



CIDAC 2011, 3 MARCH, AMSTERDAM

ORGANIZING COMMITTEE

D BAETEN, MC BOISSIER, A COPE, O
DISTLER, A GRACIE, C JORGENSEN, S
GUIDUCCI, U MUELLER-LADNER, T
PAP, K REDLICH, G SCHEIT, PP TAK

Dear Colleague,

On behalf of the organizing committee we wish to inform you that the second European course CIDAC “CLINICAL CHALLENGE IN INFLAMMATORY DISEASES ANNUAL COURSE” will be located in Amsterdam March 3, 2011 in connection with the EWRR meeting.

The course will provide an update on biotherapies, on clinical challenges in arthritis and cutting edge scientific advances in the field of immunotherapy.

The topics will cover:

- Cutting edge in RA immunopathology and immunogenetics
- Translational strategies for immune intervention in autoimmune disorders
- Improving concepts for innovative immunotherapies
- Clinical challenges for RA therapy
- Update on clinical trials for immunotherapy for RA
- Predictive medicine applied to biologics development
- Pharmacoeconomics for biologics : the point of view of the payers

As someone working in the field, we invite you to attend and present your research to the scientific and medical communities. The **extra fee to register for this lecture is 250€**. If you are interested and support this initiative, we propose that you contact **Michelle MOYA before February 15** michellemoya@orange.fr.

We look forward to seeing you in Amsterdam, March, 2011.

Best regards,

The Organizing committee

clinical challenge in inflammatory diseases annual course & MASTERCLASS

Thursday, 3 March

8h50. Welcome and introduction. **C JORGENSEN**, (University of Montpellier France).

9h-10h. Session pathophysiology of arthritis : where do we stand & new targets

- Network of inflammatory mediators: emerging targets. **A GRACIE**, (University of Glasgow-UK).
- What have whole genome scans taught us? **A COPE** (London University-UK).
- Synovitis as a mixed cellular infiltrate-which sort of cell do we have to eliminate to cure disease ? Cell-matrix interactions and synovial targeting. **T PAP** (University Hospital Muenster-Germany).

10h-10h40. Session current treatment and unmet medical needs.

- Biomarkers to predict response to specific biologics in RA patients. **PP TAK** (AMC/University of Amsterdam- Netherlands)
- Combination therapy targeting more than one pathway : is this a feasible challenge for the future. **S GUIDUCCI** (University of Florence-Italy)

Coffee break 10h40-11h

11h-12h00. Session challenges : future targets

- What are the ideal strategies to protect bone and cartilage in inflammation? **G SCHETT** (University of Erlangen-Germany)
- Strategy for optimal immunotherapy in Lupus. **MC BOISSIER** (University Paris 13-France).
- Targeting fibrosis and new perspective in scleroderma **O DISTLER** (University of Zurich, Switzerland)
- Which biologic at what time, in which patients and in which sequence? A critical discussion of treatment strategies and unmet needs: **Round table**

End of session. EWRR meeting.
